419 related articles for article (PubMed ID: 29273843)
1. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.
Edney LC; Haji Ali Afzali H; Cheng TC; Karnon J
Pharmacoeconomics; 2018 Feb; 36(2):239-252. PubMed ID: 29273843
[TBL] [Abstract][Full Text] [Related]
2. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
[TBL] [Abstract][Full Text] [Related]
3. Are the benefits of new health services greater than their opportunity costs?
Edney L; Haji Ali Afzali H; Karnon J
Aust Health Rev; 2019 Oct; 43(5):508-510. PubMed ID: 30526796
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
Chen G; Peirce V; Marsh W
Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
[TBL] [Abstract][Full Text] [Related]
5. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
Beresniak A; Dupont D
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
[TBL] [Abstract][Full Text] [Related]
6. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.
Ochalek J; Lomas J
Clin Ther; 2020 Jan; 42(1):44-59.e2. PubMed ID: 31955967
[TBL] [Abstract][Full Text] [Related]
7. The political economy of the assessment of value of new health technologies.
Karnon J; Edney L; Afzali H
J Health Serv Res Policy; 2018 Apr; 23(2):116-122. PubMed ID: 29320891
[TBL] [Abstract][Full Text] [Related]
8. Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.
Alkhatib N; Sweitzer NK; Lee CS; Erstad B; Slack M; Gharaibeh M; Karnes J; Klimecki W; Ramos K; Abraham I
Am J Cardiovasc Drugs; 2021 Mar; 21(2):205-217. PubMed ID: 32710439
[TBL] [Abstract][Full Text] [Related]
9. Informing a cost-effectiveness threshold for Saudi Arabia.
Al-Jedai AH; Lomas J; Almudaiheem HY; Al-Ruthia YSH; Alghamdi S; Awad N; Alghamdi A; Alowairdhi MA; Alabdulkarim H; Almadi M; Bunyan RF; Ochalek J
J Med Econ; 2023; 26(1):128-138. PubMed ID: 36576804
[TBL] [Abstract][Full Text] [Related]
10. A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States.
Vanness DJ; Lomas J; Ahn H
Ann Intern Med; 2021 Jan; 174(1):25-32. PubMed ID: 33136426
[TBL] [Abstract][Full Text] [Related]
11. What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study.
Harris A; Li JJ; Yong K
Pharmacoeconomics; 2016 Apr; 34(4):393-402. PubMed ID: 26610347
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
13. Should Health Economic Evaluations Undertaken from a Societal Perspective Include Net Government Spending Multiplier Effects?
Karnon J; Pekarsky B
Appl Health Econ Health Policy; 2020 Aug; 18(4):467-475. PubMed ID: 32020537
[TBL] [Abstract][Full Text] [Related]
14. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
17. Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies.
Nord E
Eur J Health Econ; 2018 Mar; 19(2):267-275. PubMed ID: 28258399
[TBL] [Abstract][Full Text] [Related]
18. Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity.
Martin S; Lomas J; Claxton K
BMJ Open; 2020 Oct; 10(10):e036411. PubMed ID: 33039987
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
